Mylan Turns To Meda In Sweden For Open Door Into Consumer Market
This article was originally published in The Tan Sheet
Executive Summary
The deal is subject to 90% of Meda shareholders tendering shares, and the two largest shareholders, accounting for about 30% of shares, already committed to the deal. Mylan will pay around $8.5bn in cash and debt and about $1.4bn in stock.
You may also be interested in...
The End Is Nigh For Mylan, But How Different Will The New Company Be?
Mylan will be merged into a new company with Pfizer’s Upjohn, closing the chapter on a generic drug powerhouse that will be remembered as much for scandal as success.
Cold-Eeze Deal Puts Homeopathic Brand At Center Of Mylan Consumer Business
The $50m deal adds a homeopathic brand to Mylan's portfolio that will lead its US consumer lineup; ProPhase will focus on dietary supplements; leave behind seasonal-demand products.
Mylan's Cold-Eeze OTC Acquisition Aims To Leverage Respiratory Expertise
Mylan could tap respiratory product experience to develop line extensions to the homeopathic product, now seen as the centerpiece of its US consumer business.